Exelixis Inc Repayments of Long-Term Debt
Exelixis Inc (EXEL) reported Repayments of Long-Term Debt of $0 for the 12-month period ending 2020-01-03, per its 10-K filed 2020-02-25.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2020-02-25
- Exelixis Inc repayments of long-term debt for the quarter ending 2018-12-28 was $0.00.
- Exelixis Inc repayments of long-term debt for the quarter ending 2018-09-28 was $0.00.
- Exelixis Inc repayments of long-term debt for the quarter ending 2018-06-29 was $0.00, a 100.00% decline year-over-year.
- Exelixis Inc repayments of long-term debt for the quarter ending 2018-03-30 was $0.00, a 100.00% decline year-over-year.
- Exelixis Inc repayments of long-term debt for fiscal 2020 was $0.00.
- Exelixis Inc repayments of long-term debt for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- Exelixis Inc repayments of long-term debt for fiscal 2017 was $185.79M, a 32210.96% increase from fiscal 2016.
- Exelixis Inc repayments of long-term debt for fiscal 2016 was $575.00K, a 86.88% decline from fiscal 2016.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|
| 2020-01-03 | $0.00 10-K · filed 2020-02-25 | |||
| 2018-12-28 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $0.00 derived: sum of 2 quarters · filed 2020-02-25 | $0.00 derived: sum of 3 quarters · filed 2020-02-25 | $0.00 10-K · filed 2020-02-25 |
| 2018-09-28 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $0.00 derived: sum of 2 quarters · filed 2018-11-01 | $0.00 10-Q · filed 2018-11-01 | $0.00 derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-29 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $0.00 10-Q · filed 2018-08-01 | $0.00 derived: sum of 3 quarters · filed 2020-02-25 | $0.00 derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-30 | $0.00 10-Q · filed 2018-05-02 | $0.00 derived: sum of 2 quarters · filed 2020-02-25 | $0.00 derived: sum of 3 quarters · filed 2020-02-25 | |
| 2017-12-29 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $0.00 derived: sum of 2 quarters · filed 2020-02-25 | $185.79M 10-K · filed 2020-02-25 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $185.79M 10-Q · filed 2017-11-01 | ||
| 2017-09-29 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $105.79M derived: sum of 2 quarters · filed 2018-11-01 | $185.79M 10-Q · filed 2018-11-01 | |
| 2017-06-30 | $105.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $185.79M 10-Q · filed 2017-08-02 | ||
| 2017-03-31 | $80.00M 10-Q · filed 2018-05-02 | |||
| 2016-12-30 | $575.00K 10-K · filed 2019-02-22 | |||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $0.00 10-Q · filed 2017-11-01 | ||
| 2016-06-30 | $0.00 10-Q · filed 2017-08-02 | |||
| 2016-01-01 | $4.38M 10-K · filed 2018-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |